Overview of Flexiplen Plus

Quick Facts

Property	Description
Active ingredient	Diclofenac, Pridinol
Form	Tablets (Coated), Soft Capsules
Pharmacological class	NSAID and Centrally Acting Muscle Relaxant
Common use	Acute painful inflammation with muscle spasm
Origin	Synthetic

What Type of Medicine is Flexiplen Plus?

Flexiplen Plus is a fixed-dose combination drug that acts simultaneously as a Non-Steroidal Anti-Inflammatory Drug (NSAID) and a centrally acting muscle relaxant. This synthetic formulation is strategically designed to address both pain and muscular rigidity within a single preparation. Diclofenac, the NSAID component, is chemically classified as a phenylacetic acid derivative, exhibiting properties that are effective anti-inflammatory and analgesic action. The dual nature of this medicine means it is intended for complex musculoskeletal involvement where both inflammation and stiffness are contributing factors.

Composition and Available Forms of Flexiplen Plus

The active components in the product are Diclofenac and Pridinol. Diclofenac is a widely prescribed NSAID used for treating acute and chronic pain associated with inflammatory conditions, especially those involving the musculoskeletal system. The Pridinol component is pharmacologically an anticholinergic agent that functions as a muscle relaxant. Flexiplen Plus is typically supplied as solid pharmaceutical preparations, such as coated tablets or soft capsules, ensuring efficient delivery of both active ingredients via oral administration.

General Purpose and Synergistic Benefit

The general purpose of this combination medicine is to offer a comprehensive therapeutic approach to acute painful inflammatory processes where concurrent muscle contractures are present. The dual action provides a synergistic strategy: Diclofenac curtails inflammation by inhibiting prostaglandins, while Pridinol relieves involuntary spasms by modulating nerve signals. This combined effect ensures that the treatment simultaneously targets the pain source and the associated skeletal muscle tension, offering a balanced intervention for complex discomfort.

Regulatory References

What side effects are possible with Flexiplen Plus?

The safety profile for Flexiplen Plus, a combination of Diclofenac and Pridinol, is primarily derived from the well-documented regulatory profile of its Non-Steroidal Anti-Inflammatory Drug (NSAID) component, Diclofenac, as classified by government health authorities (e.g., EMA, FDA).

Adverse Reaction Groupings

Adverse reactions are formally organized into categories based on the affected System-Organ Class and their official frequency, ranging from Very Common to Very Rare (or Not Known). Common reactions often involve the Gastrointestinal System (e.g., nausea, vomiting, diarrhoea, abdominal pain) and the Nervous System (e.g., headache, dizziness).

Serious Adverse Reactions and Safety Patterns

The prescribing information highlights specific serious adverse reactions documented for NSAIDs. These include potentially fatal events such as Gastrointestinal Bleeding, Ulceration, or Perforation, which can occur at any time during treatment, often without prior warning symptoms. Additionally, the medicine may be associated with an increased risk of serious Cardiovascular Thrombotic Events (e.g., Myocardial Infarction and Stroke), particularly when used at higher doses and for long durations of exposure, as noted in official regulatory reviews.

Population-Specific Constraints

Official labels detail safety constraints for certain patient groups. The medicine is generally contraindicated in the last trimester of pregnancy due to risks to the fetus. Elderly patients are documented as having a significantly increased frequency and seriousness of adverse reactions, particularly fatal gastrointestinal bleeding. Use is also restricted or contraindicated in patients with established conditions such as active gastrointestinal ulceration and severe heart failure (NYHA class II-IV). These restrictions define the specific limits of the drug's approved safety characteristics.

Overdose and Emergency Response

Overdose and when to seek help

Suspected overdose of Flexiplen Plus necessitates immediate medical attention. Regulatory documents describe the overdose presentation as a combination of toxicity from both the NSAID and anticholinergic components.

Manifestations may include gastrointestinal symptoms such as nausea, vomiting, abdominal pain, and potential bleeding. Additionally, symptoms of anticholinergic toxicity are documented, including altered mental status (confusion, agitated delirium), blurred vision due to pupil dilation (mydriasis), dry mouth, and urinary retention. More severe central nervous system effects include seizures and coma.

Officially documented life-threatening outcomes include acute renal or hepatic injury, severe gastrointestinal perforation, and cardiovascular complications such as cardiac conduction abnormalities and circulatory collapse. Patients with pre-existing organ impairments and the elderly are officially noted to be at higher risk for severe outcomes.

Urgent medical help must be sought when any overdose is suspected, and emergency services must be contacted immediately if symptoms are severe or life-threatening. Official management involves symptomatic and supportive measures, as no specific antidote is known. Decontamination procedures may include the administration of activated charcoal or gastric lavage. Continuous ECG monitoring is required to assess and manage potential cardiac risk.

Therapeutic Uses of Flexiplen Plus

What Flexiplen Plus treats: main uses and benefits

The medication is commonly used in clinical contexts that involve acute or disruptive symptom patterns in the musculoskeletal system, such as sudden episodes of back pain or discomfort from soft tissue injuries. Its NSAID component, Diclofenac, is indicated for the short-term treatment of acute conditions such as post-traumatic pain and inflammation as well as post-operative pain. The combination is applied in situations where management of both types of symptoms is appropriate.

This medicine is commonly used to help manage symptom clusters related to acute inflammatory episodes and painful muscle contracture. It is relevant in situations involving conditions such as acute lumbago, sciatica, strains, and sprains.

It is relevant for managing symptom clusters that may become intense or disruptive. As a patient might feel:

“The combination may assist with easing the overall symptom burden when both inflammation and muscle tension interfere with daily functioning.”

The medicine may provide support that helps ease this burden, contributing to improved day-to-day comfort during periods of heightened symptoms and assists with maintaining functional stability.

Quick Fact: Relief for Dual Discomfort

Property	Description
Symptom Focus	Pain, Inflammation, and Muscle Spasm
Use Context	Acute musculoskeletal episodes
Primary Benefit	Supportive symptom management

Regulatory References

Medsafe (New Zealand Medicines and Medical Devices Safety Authority) on Diclofenac

Eligibility and Restrictions for Use

Flexiplen Plus is officially approved for use in Adults and is subject to stringent limitations based on pre-existing conditions and life stage, as defined in government regulatory labeling.

Contraindicated Populations

The medicine is contraindicated and must not be used by patients with:

Established Cardiovascular Disease: Including congestive heart failure (NYHA Class II-IV), ischemic heart disease, peripheral arterial disease, or cerebrovascular disease.
Severe Organ Dysfunction: Those with severe hepatic failure or severe renal impairment.
Gastrointestinal Integrity Issues: Patients with an active or history of gastrointestinal ulceration, bleeding, or perforation linked to NSAID use.
Hypersensitivity: Known allergy to Diclofenac, Pridinol, or other NSAIDs, including aspirin-sensitive asthma.
Anticholinergic-Sensitive Conditions: Including glaucoma, prostate hypertrophy, or conditions causing urinary or gastrointestinal obstruction (due to the Pridinol component).

Age and Developmental Restrictions

The combination is generally not established for safety and effectiveness in children and adolescents under 18 and is not recommended for this age group. Older adults require caution and close monitoring, often necessitating the lowest effective dose due to increased risk of serious gastrointestinal and renal events. Use in late pregnancy (from 30 weeks gestation onward) is contraindicated due to risk to the fetus, and use during breastfeeding is generally avoided.

What should I know about interactions with other medicines?

The official interaction profile for Flexiplen Plus is largely defined by the Diclofenac (NSAID) component, as documented in governmental regulatory sources. These interactions are categorized based on their mechanism and resulting clinical constraint.

Interaction Scope

Category	Official Regulatory Information
Medicinal product categories with documented interactions	NSAIDs, Anticoagulants, Antiplatelet Agents, SSRIs/SNRIs, Antihypertensive Agents (ACE Inhibitors, ARBs), Diuretics, Anticholinergic Agents.
Specific interacting medicines (if explicitly listed)	Aspirin, Methotrexate, Digoxin, Lithium, Cyclosporine, Tacrolimus.
Mechanistic basis of interactions	Reduced Clearance (increasing plasma concentrations of Lithium, Methotrexate); Additive Risk (bleeding with Anticoagulants); Pharmacodynamic Antagonism (diminishing effects of Antihypertensives, Diuretics).
Population-specific interaction notes	Concomitant use with ACE Inhibitors or ARBs in the elderly or those with renal impairment may result in a deterioration of renal function.

Interaction Classifications (High-Level)

Category	Official Regulatory Information
Interaction severity classification	Contraindicated: Use for perioperative pain in CABG surgery. Serious/Not Recommended: Concomitant use with other systemic NSAIDs or analgesic doses of Aspirin.
Interaction-context constraints	Use with Alcohol increases the risk of serious gastrointestinal bleeding. The Pridinol component can have additive antimuscarinic effects when combined with other anticholinergic agents.

Resulting Interaction Structure

Official regulatory statements restrict co-administration with other NSAIDs and analgesic doses of Aspirin due to compounded gastrointestinal risk. The medicine can cause an increase in the plasma concentrations of substances such as Lithium and Digoxin by reducing their clearance. Diclofenac may also diminish the therapeutic effects of certain Antihypertensive Agents and Diuretics. These constraints define the required use limitations based on official regulatory classifications.

Mechanism of Action

Targeted Inhibition of Cyclooxygenase (COX) Enzymes

Flexiplen Plus exerts its action primarily within domains involving enzyme-mediated signaling, specifically by inhibiting Cyclooxygenase (COX) enzymes.

This interaction blocks an initial molecular step in the cascade: the conversion of arachidonic acid into prostaglandins. Prostaglandins are lipid mediators that influence the activity state of targeted biological pathways, particularly those involved in peripheral signaling.

Modulation of Inflammatory Mediator Cascades

By suppressing prostaglandin synthesis, the drug initiates a mechanistic cascade that modifies the concentration or signaling capability of specific mediators within the environment. This intervention alters signaling dynamics within molecular pathways, which is relevant in systems requiring rapid adjustment of humoral pathway activity.

Influence on Peripheral Regulator Systems

The mechanism engages in broader pathway modulation across peripheral systems. This is associated with altered activity patterns within targeted pathways, used to modulate activity within central or peripheral pathways that operate under heightened conditions. The overall effect involves the engagement of regulatory mechanisms and the adjustment of key signaling sequences.

Dosage and Administration Information

How to Use Flexiplen Plus: Administration Guidelines

Flexiplen Plus, a fixed-dose combination containing Diclofenac 50 mg and Pridinol 4 mg, is administered via the oral route as a coated tablet or capsule. The usage protocol aligns with the established safety profile for the primary drug component, Diclofenac.

Dosing and Scheduling Principles

Administration Scope	Instruction
Standard Adult Dose	One unit dose (tablet/capsule) is typically taken two to three times per day.
Maximum Daily Limit	The total daily dose of the Diclofenac component should not exceed 150 mg, restricting intake to three unit doses daily.
Intake Timing	The unit dose should be swallowed with, or immediately following, food to guide optimal ingestion conditions.
Duration of Use	Treatment is generally intended to be short-term, adhering to the principle of using the lowest effective dose for the shortest possible duration.

The unit dose must be swallowed whole with a liquid and should not be crushed, broken, or chewed. This procedural requirement ensures that the full unit dose is administered as intended by the pharmaceutical formulation.

For specific patient populations, caution is emphasized. Use in older adults requires specific attention, mandating the use of the lowest effective dosage for the briefest duration necessary due to altered physiological response. Furthermore, administration is generally not recommended for pediatric patients due to the standard high dosage strength of the combination product.

Recent Clinical Evidence

Research evidence / Overview of studies for Flexiplen Plus

Evidence for Acute Painful Inflammation with Muscle Spasm

Research has explored the use of combined therapy, such as an anti-inflammatory drug and a muscle relaxant, in conditions characterized by fluctuating or episodic manifestations that involve both physical discomfort and muscle contractures. Studies are primarily short-term Randomized Controlled Trials (RCTs) or systematic reviews focusing on these episodic symptom patterns. This research examined outcomes related to physical discomfort and the body’s overall functional status.

The main outcomes related to physical discomfort were measured by having patients rate their pain intensity using validated scales. Additionally, studies evaluated the level of functional limitation and physical disability using standardized assessments like the Oswestry Disability Index. Research describes patterns observed in the studies related to how patients reported their experience and how symptoms evolved in the observed populations during periods of increased symptom activity.

Studies Examining Diclofenac and Muscle Relaxants

The evidence base for the fixed-dose combination of Diclofenac and Pridinol is characterized by pilot studies and research on the individual components. Findings were mixed across the board because much of the combination research uses a different muscle relaxant alongside Diclofenac, which contributes to study heterogeneity. The existing body of evidence was observed in acute symptom patterns and provides limited insight into the long-term changes.

A large portion of the evidence for this combination strategy is drawn from systematic reviews and RCTs that focus on the individual active components. Diclofenac monotherapy was studied for its impact on outcomes linked to inflammatory or irritative states in conditions associated with acute or disruptive episodes. Similarly, Pridinol monotherapy was evaluated in studies observing temporary changes in muscle tone. Comparative evidence is lacking for the specific oral Flexiplen Plus combination against placebo or other common therapies.

What Research Remains Uncertain

The evidence quality varies across studies for the specific oral Flexiplen Plus fixed-dose combination because it relies heavily on extrapolation from studies of the individual components or trials using different combinations. Sample sizes were modest in the most relevant pilot data, and follow-up durations were limited to the acute phase of discomfort. This means that evidence highlights what is known regarding short-term patterns but remains limited in predicting personal outcomes over an extended time.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Flexiplen Plus (FAQ)

Q: Are there any food or drinks that should be avoided with Flexiplen Plus?

Official product information states that the use of alcohol is strongly advised against. This restriction is in place because combining alcohol with the NSAID component may significantly increase the risk of serious gastrointestinal bleeding. Regarding intake timing, the drug label requires the medicine to be taken with, or immediately following, food.

Q: What does the research say about the long-term use of Flexiplen Plus?

Regulatory guidance for this type of medicine operates on the principle of using the lowest effective dose for the shortest possible duration. This is a safety requirement reflecting that the risk of serious adverse reactions, such as gastrointestinal bleeding and cardiovascular events, is observed to increase with prolonged use.

Q: What is the approved use for Flexiplen Plus in my country?

The medicine is officially indicated for the treatment of acute painful inflammatory processes where concurrent muscle spasms are present. Official product information describes this general therapeutic use. Because regulatory status and local indications can vary, the specific approved use may need verification against the prescribing information issued by the national health authority.

Q: What are the official sources for patient information about Flexiplen Plus?

Authoritative and factual patient information is primarily provided by government health agencies. These sources include the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and resources like NIH MedlinePlus. These bodies publish the official drug labels and Summary of Product Characteristics (SmPC).

Q: How long does it take for Flexiplen Plus to start working?

Official pharmacokinetic data provides insight into the absorption profile of the medicine. For the Diclofenac component, the time to reach maximum concentration in the bloodstream is typically within one to two hours after the tablet is taken.

Q: Is feeling tired a normal side effect of Flexiplen Plus?

Official safety listings for this medicine's components commonly include effects on the nervous system, such as dizziness and drowsiness (somnolence). While the term “tiredness” specifically may not be listed, these related effects are documented in regulatory sources and may impact alertness.

Q: Is Flexiplen Plus a narcotic or addictive medicine?

According to official classification, the medicine is generally recognized as a Non-Controlled Substance. The active components, including the NSAID Diclofenac, are not designated as narcotics or scheduled controlled drugs by regulatory authorities.

Q: Does Flexiplen Plus have a black box warning?

The Diclofenac component of the medicine is associated with a Boxed Warning in U.S. regulatory information. This warning is used to highlight serious safety risks, particularly involving the potential for life-threatening events related to the cardiovascular system and the gastrointestinal tract.

Q: How is Flexiplen Plus eliminated from the body?

Pharmacokinetic data from official sources describes how the medicine is processed. The components are primarily metabolized in the liver and eliminated from the body mostly through the urine and, to a lesser extent, through bile and feces.

Q: What is the difference between a side effect and an adverse reaction for Flexiplen Plus?

In the language of regulatory bodies, the term Adverse Reaction (or Adverse Event) is the official classification used to describe any undesired outcome or health problem associated with taking the medicine. Official safety listings categorize these events based on their severity and frequency.

Q: Can Flexiplen Plus affect sleep patterns?

Official regulatory safety profiles have documented effects on the Nervous System that include dizziness and drowsiness. These documented effects are noted as potentially impacting normal sleep or alertness patterns.

Q: Does taking Flexiplen Plus make you sensitive to the sun?

While not classified as a common effect, certain regulatory listings include reports of photosensitivity reactions associated with the NSAID component of the medicine. Photosensitivity means an increased or unusual sensitivity to sunlight.

Q: Is Flexiplen Plus available over the counter or is it prescription only?

The dispensing status of this medicine, whether it requires a prescription or is available over-the-counter, is a regulatory classification that varies by country. Due to the active components and dosage strength, the combination product generally requires a prescription in most territories.

Q: Does Flexiplen Plus affect blood sugar levels?

Regulatory documents note the need for careful monitoring when the medicine is taken concurrently with certain anti-diabetic medicines due to potential interaction. Furthermore, rare instances of both hyperglycemia (high blood sugar) and hypoglycemia (low blood sugar) have been listed in adverse reaction reports.

Q: Are there any known drug-herb interactions with Flexiplen Plus?

Official interaction profiles primarily focus on prescription medicines, but regulatory warnings exist regarding potential interactions with certain herbal preparations. Specifically, there are general warnings related to the additive antiplatelet effects of some herbs (such as Ginkgo biloba) when combined with NSAIDs.

Q: Is it common to experience dry mouth while taking Flexiplen Plus?

Yes, dry mouth, technically known as xerostomia, is listed as an official common adverse reaction in the regulatory documents. This effect is associated with the anticholinergic component (Pridinol) of the medicine.

Q: Is Flexiplen Plus safe for people with high cholesterol?

Regulatory documents state that use of the medicine requires caution in patients with pre-existing risk factors for cardiovascular disease. High cholesterol is noted as a relevant cardiovascular risk factor that regulatory bodies indicate must be taken into account during the overall risk assessment.

Q: Do studies show a difference in effect based on age or gender?

Official product information notes that the elderly population requires specific caution, which often necessitates dose adjustment. This is due to altered physiological response and an increased risk of adverse reactions documented in this age group. Differences based on gender are not typically highlighted in general regulatory summaries.

Q: Can Flexiplen Plus cause weight gain or loss?

Regulatory safety documents have included rare reports of weight changes (either gain or loss) under the reported adverse reactions associated with the medicine. This is not classified as a common side effect.

How should Flexiplen Plus be stored and disposed of?

Regulatory documents define the official requirements for storing and disposing of Flexiplen Plus (Diclofenac/Pridinol), primarily based on standards for its NSAID component.

Storage Condition	Requirement
Temperature	Store at room temperature, typically below 25 C; Keep from freezing.
Protection	Keep in the original container, tightly closed, and protected from excess moisture and light.
Child Safety	Must be stored out of the sight and reach of children.
Disposal	Do not flush or dispose of in household trash; discard in accordance with local regulations or a government-approved drug take-back program.

These official rules ensure product stability until the expiry date and prevent accidental exposure or environmental contamination. The labeled stability is only guaranteed when the medicine is stored under these explicit environmental and container constraints.

Flexiplen Plus